Thoracic Skeletal Muscle Is Associated With Adverse Outcomes After Lobectomy for Lung Cancer
- PMID: 29408306
- DOI: 10.1016/j.athoracsur.2018.01.013
Thoracic Skeletal Muscle Is Associated With Adverse Outcomes After Lobectomy for Lung Cancer
Abstract
Background: Assessment of risk associated with lung cancer resection is primarily based on evaluation of cardiopulmonary function and remains imprecise. We investigated the relationship between thoracic muscle and early outcomes after lobectomy.
Methods: Cross-sectional area of skeletal muscle was measured at the level of the fifth thoracic vertebra on computed tomography in 135 consecutive patients before lobectomy for lung cancer. Patients were stratified into low and high muscle groups using the sex-specific muscle median. Primary outcome was a composite of any postoperative complication as per The Society of Thoracic Surgeons General Thoracic Surgical Database. Secondary outcomes included postoperative respiratory complications, postoperative intensive care unit admission, hospital length of stay, and hospital readmission within 30 days of hospital discharge. The χ2 test, adjusted multivariable regression analysis, and likelihood ratio test were performed.
Results: Patients with low muscle were significantly more likely to have any postoperative complication and respiratory postoperative complications. Although postoperative intensive care unit admission was similar for low muscle and high muscle groups, low muscle patients had longer hospital length of stay and a higher rate of hospital readmission. Adjusted multivariable regression revealed the independent association of thoracic muscle with all outcomes. The likelihood ratio test suggested that thoracic muscle adds predictive capability to information captured by preoperative pulmonary function testing.
Conclusions: Low thoracic muscle is independently associated with increased postoperative complications and health care utilization among patients undergoing lobectomy for lung cancer. Evaluation of thoracic muscle may enhance risk prediction models.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Comment in
-
Statistical Commentary.Ann Thorac Surg. 2018 May;105(5):1515. doi: 10.1016/j.athoracsur.2018.02.004. Epub 2018 Mar 6. Ann Thorac Surg. 2018. PMID: 29501656 No abstract available.
-
Sarcopenia is a potential factor for optimized treatment selection for elderly patients with early stage non-small cell lung cancer.J Thorac Dis. 2019 Mar;11(Suppl 3):S443-S445. doi: 10.21037/jtd.2018.11.44. J Thorac Dis. 2019. PMID: 30997243 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
